<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Edwards Lifesciences Corp — News on 6ix</title>
<link>https://6ix.com/company/edwards-lifesciences-corp</link>
<description>Latest news and press releases for Edwards Lifesciences Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/edwards-lifesciences-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835656078dffbe2df0f00e4.webp</url>
<title>Edwards Lifesciences Corp</title>
<link>https://6ix.com/company/edwards-lifesciences-corp</link>
</image>
<item>
<title>Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-to-present-at-the-bofa-securities-2026-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-to-present-at-the-bofa-securities-2026-health-care-conference</guid>
<pubDate>Tue, 28 Apr 2026 11:05:00 GMT</pubDate>
<description>IRVINE, Calif., April 28, 2026--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026.</description>
</item>
<item>
<title>Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-to-host-earnings-conference-call-on-april-23-2026</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-to-host-earnings-conference-call-on-april-23-2026</guid>
<pubDate>Thu, 16 Apr 2026 11:05:00 GMT</pubDate>
<description>IRVINE, Calif., April 16, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.</description>
</item>
<item>
<title>Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/two-year-data-on-edwards-lifesciences-evoque-system-continue-to-demonstrate-significant-and-sustained-patient-benefits</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/two-year-data-on-edwards-lifesciences-evoque-system-continue-to-demonstrate-significant-and-sustained-patient-benefits</guid>
<pubDate>Mon, 30 Mar 2026 14:00:00 GMT</pubDate>
<description>NEW ORLEANS, March 30, 2026--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025).</description>
</item>
<item>
<title>Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-advances-structural-heart-care-through-innovation-and-purpose</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-advances-structural-heart-care-through-innovation-and-purpose</guid>
<pubDate>Thu, 26 Feb 2026 14:15:00 GMT</pubDate>
<description>IRVINE, Calif., February 26, 2026--At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access</description>
</item>
<item>
<title>NEW SURVEY BY EDWARDS LIFESCIENCES UNCOVERS JUST HOW MUCH AMERICANS KNOW ABOUT THEIR HEART HEALTH</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/new-survey-by-edwards-lifesciences-uncovers-just-how-much-americans-know-about-their-heart-health</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/new-survey-by-edwards-lifesciences-uncovers-just-how-much-americans-know-about-their-heart-health</guid>
<pubDate>Tue, 24 Feb 2026 13:35:00 GMT</pubDate>
<description>How many times have you found yourself breathless after a single flight of stairs, struggling with grocery bags you once carried with ease or feeling your heart pound rapidly after the smallest exertion? A new survey conducted for Edwards Lifesciences by Talker Research explores how older adults think about their health — from the small signs and moments brushed off as "just aging" with a promise to "deal with it later," to proactively discussing health concerns with their doctor after 65, revea</description>
</item>
<item>
<title>Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-to-present-at-the-barclays-and-leerink-partners-global-healthcare-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-to-present-at-the-barclays-and-leerink-partners-global-healthcare-conferences</guid>
<pubDate>Thu, 19 Feb 2026 12:05:00 GMT</pubDate>
<description>IRVINE, Calif., February 19, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences:</description>
</item>
<item>
<title>Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-present-citi-2026-120500278</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-present-citi-2026-120500278</guid>
<pubDate>Fri, 13 Feb 2026 12:05:00 GMT</pubDate>
<description>IRVINE, Calif., February 13, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026.</description>
</item>
<item>
<title>Edwards Lifesciences Reports Fourth Quarter Results</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-reports-fourth-quarter-211500853</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-reports-fourth-quarter-211500853</guid>
<pubDate>Tue, 10 Feb 2026 21:15:00 GMT</pubDate>
<description>IRVINE, Calif., February 10, 2026--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025.</description>
</item>
<item>
<title>Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-host-earnings-conference-120500780</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-host-earnings-conference-120500780</guid>
<pubDate>Tue, 03 Feb 2026 12:05:00 GMT</pubDate>
<description>IRVINE, Calif., February 03, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results.</description>
</item>
<item>
<title>Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-present-td-cowen-120500279</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-present-td-cowen-120500279</guid>
<pubDate>Mon, 02 Feb 2026 12:05:00 GMT</pubDate>
<description>IRVINE, Calif., February 02, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 46th Annual Health Care Conference on Monday, Mar. 2, 2026.</description>
</item>
<item>
<title>Edwards Comments on JenaValve Acquisition</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-comments-jenavalve-acquisition-234800061</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-comments-jenavalve-acquisition-234800061</guid>
<pubDate>Fri, 09 Jan 2026 23:48:00 GMT</pubDate>
<description>IRVINE, Calif., January 09, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company’s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve.</description>
</item>
<item>
<title>FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/fda-approves-edwards-lifesciences-sapien-140000005</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/fda-approves-edwards-lifesciences-sapien-140000005</guid>
<pubDate>Tue, 23 Dec 2025 14:00:00 GMT</pubDate>
<description>IRVINE, Calif., December 23, 2025--Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and Drug Administration (FDA) approval for the treatment of mitral regurgitation (MR). The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is indicated for the treatment of symptomatic moderate-to-severe or severe MR in patients who are deemed unsuitable fo</description>
</item>
<item>
<title>Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-present-44th-annual-120500959</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-present-44th-annual-120500959</guid>
<pubDate>Thu, 18 Dec 2025 12:05:00 GMT</pubDate>
<description>IRVINE, Calif., December 18, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026.</description>
</item>
<item>
<title>Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-reaffirms-strategy-sustainable-140000256</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-reaffirms-strategy-sustainable-140000256</guid>
<pubDate>Thu, 04 Dec 2025 14:00:00 GMT</pubDate>
<description>IRVINE, Calif., December 04, 2025--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunit</description>
</item>
<item>
<title>Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-champions-american-heart-association-210000392</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-champions-american-heart-association-210000392</guid>
<pubDate>Sun, 09 Nov 2025 21:00:00 GMT</pubDate>
<description>NEW ORLEANS, November 09, 2025--Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many driven by delayed diagnosis or treatment.</description>
</item>
<item>
<title>Edwards Lifesciences Announces CFO Transition Plan</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-announces-cfo-transition-201500651</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-announces-cfo-transition-201500651</guid>
<pubDate>Thu, 30 Oct 2025 20:15:00 GMT</pubDate>
<description>IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company’s chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role.</description>
</item>
<item>
<title>Edwards Lifesciences Reports Third Quarter Results</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-reports-third-quarter-201300577</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-reports-third-quarter-201300577</guid>
<pubDate>Thu, 30 Oct 2025 20:13:00 GMT</pubDate>
<description>IRVINE, Calif., October 30, 2025--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025.</description>
</item>
<item>
<title>Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/successful-patient-outcomes-demonstrated-edwards-190600679</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/successful-patient-outcomes-demonstrated-edwards-190600679</guid>
<pubDate>Mon, 27 Oct 2025 19:06:00 GMT</pubDate>
<description>SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement</description>
</item>
<item>
<title>Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-sapien-3-tavr-delivers-182200671</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-sapien-3-tavr-delivers-182200671</guid>
<pubDate>Mon, 27 Oct 2025 18:22:00 GMT</pubDate>
<description>SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards’ leadership in setting the standard for lasting valve performance and excellent patien</description>
</item>
<item>
<title>Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025</title>
<link>https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-host-earnings-conference-110500662</link>
<guid isPermaLink="true">https://6ix.com/company/edwards-lifesciences-corp/news/edwards-lifesciences-host-earnings-conference-110500662</guid>
<pubDate>Thu, 23 Oct 2025 11:05:00 GMT</pubDate>
<description>IRVINE, Calif., October 23, 2025--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.</description>
</item>
</channel>
</rss>